The Latest Breaking News from Novo Nordisk

Upgrades

TGA urges GPs to limit prescriptions to approved use for diabetes management amid surge in off-label demand

In today's IBD Screen Of The Day, the Stocks That Funds Are Buying filter reveals four compelling growth stocks near buy points of new bases. Three are in the energy field and one is a drugmaker. Novo Nordisk (NVO) has waffled a bit after breaking out above the 117.45 buy…

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.28% on an annualized basis producing an average annual return of 14.59%. Currently, Novo Nordisk has a market capitalization of $268.66 billion.

Novo Nordisk will report first-quarter earnings on May 4.

The FDA has approved Novo Nordisk A/S's (NYSE:NVO) 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes.  Ozempic is now approved in the US at 0.5 mg,1.0 mg, and 2.0 mg doses to treat type 2 diabetes in adults. Further, Ozempic is indicated to…

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.52% on an annualized basis producing an average annual return of 14.65%. Currently, Novo Nordisk has a market capitalization of $250.29 billion.

Novo Nordisk A/S (NYSE: NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.

Novo Nordisk A/S (NYSE: NVO)